<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779739</url>
  </required_header>
  <id_info>
    <org_study_id>FaVR@UAB2012</org_study_id>
    <nct_id>NCT01779739</nct_id>
  </id_info>
  <brief_title>Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy</brief_title>
  <acronym>FaVR</acronym>
  <official_title>Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: UAB Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, double-blind, randomized controlled trial evaluating the change in
      sexual function in women undergoing vaginal repair for pelvic organ prolapse. Participants
      will be sexually active women who agree to randomization to having perineorrhaphy added to
      or excluded from their surgical repair. We hypothesize that sexual function will improve
      more significantly in women undergoing vaginal repair with perineorrhaphy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in sexual function as measured by validated questionnaire</measure>
    <time_frame>6 months and 12 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Validated questionnaires will be administered prior to surgery, as well as at intervals after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolapse recurrence</measure>
    <time_frame>6 months, 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A composite outcome score to define success of prolapse surgery will be applied to subjects at 6 and 12 months specifically looking for return of prolapse symptoms, anatomic recurrence, and need for retreatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Sexual Function</condition>
  <arm_group>
    <arm_group_label>No perineorrhaphy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will not have a perineorrhaphy procedure added to the vaginal prolapse repair</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perineorrhaphy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will have a perineorrhaphy added to the vaginal repair of prolapse</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Perineorrhaphy</intervention_name>
    <description>Procedure to build up the vaginal opening</description>
    <arm_group_label>Perineorrhaphy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sexually active

          -  genital hiatus measured between 4 and 6 centimeters

          -  desires sexual function

          -  undergoing vaginal repair with native tissues

          -  agrees to use vaginal estrogen for 12 months after surgery

        Exclusion Criteria:

          -  genital hiatus &gt; 6 cm

          -  planned obliterative procedure

          -  perineal body length &lt;0.5cm

          -  disrupted external anal sphincter
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candace Y Parker-Autry, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holly E Richter, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Velria Willis, RN</last_name>
    <phone>205975-8522</phone>
    <email>vwillis@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Candace Y Parker-Autry, MD</last_name>
    <phone>3367163779</phone>
    <email>cparkera@wakehealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly E Richter, PhD, MD</last_name>
      <phone>205-934-7874</phone>
      <email>hrichter@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Velria Willis, RN</last_name>
      <phone>2059758522</phone>
      <email>vwillis@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Holly E Richter, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Candace Parker-Autry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>R. Edward Varner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaginal prolapse</keyword>
  <keyword>sexual function</keyword>
  <keyword>sexual dysfunction</keyword>
  <keyword>prolapse surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
